Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
äŒæ¥ã³ãŒãTLX
äŒç€ŸåTelix Pharmaceuticals Ltd
äžå Žæ¥Nov 15, 2017
æé«çµå¶è²¬ä»»è
ãCEOãOrtiz (Raphaeel)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°55 Flemington Road
éœåžMELBOURNE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœAustralia
éµäŸ¿çªå·3051
é»è©±çªå·61390933855
ãŠã§ããµã€ãhttps://telixpharma.com/
äŒæ¥ã³ãŒãTLX
äžå Žæ¥Nov 15, 2017
æé«çµå¶è²¬ä»»è
ãCEOãOrtiz (Raphaeel)